NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
GeoVax, Inc.
CTI BioPharma
Revimmune
Direct Biologics, LLC
BioAegis Therapeutics Inc.
Vascular Biogenics Ltd. operating as VBL Therapeutics
biotx.ai GmbH